Steven Quay Biography and Net Worth

Chairman of the Board and Chief Executive Officer of Atossa Genetics

Dr. Quay has served as Chief Executive Officer, President and Chairman of the Board of Directors of the Company since the Company was incorporated in April 2009. Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, completed both an internship and residency in anatomic pathology at Massachusetts General Hospital, a Harvard Medical School teaching hospital, and is a former faculty member of the Department of Pathology, Stanford University School of Medicine.

Dr. Quay is a named inventor on 96 U.S. patents, more than 900 worldwide patent filings, and is named inventor on patents covering five pharmaceutical products that have been approved by the U.S. Food and Drug Administration. Dr. Quay received an M.D. in 1977 and a Ph.D. in 1975 from the University of Michigan. He received his B.A. degree in biology, chemistry and mathematics from Western Michigan University in 1971. He was selected to serve on the Company’s Board of Directors because of his role as a founder of the Company, as well as his qualifications as a physician and the principal researcher overseeing the clinical and regulatory development of the Company’s pharmaceutical programs.

What is Steven C. Quay's net worth?: The estimated net worth of Steven C. Quay is at least $2.01 thousand as of May 21st, 2025. Dr. Quay owns 926 shares of Atossa Genetics stock worth more than $2,006 as of October 1st. This net worth estimate does not reflect any other investments that Dr. Quay may own. Learn More about Steven C. Quay's net worth.
How do I contact Steven C. Quay?: The corporate mailing address for Dr. Quay and other Atossa Genetics executives is 1448 NW Market Street, Suite 500, Seattle, WA, 98107. Atossa Genetics can also be reached via phone at (206) 588-0256 and via email at [email protected]. Learn More on Steven C. Quay's contact information.
Has Steven C. Quay been buying or selling shares of Atossa Genetics?: Steven C. Quay has not been actively trading shares of Atossa Genetics over the course of the past ninety days. Most recently, on Wednesday, May 21st, Steven C. Quay bought 749 shares of Atossa Genetics stock. The stock was acquired at an average cost of $13.20 per share, with a total value of $9,886.80. Following the completion of the transaction, the chief executive officer now directly owns 926 shares of the company's stock, valued at $12,223.20. Learn More on Steven C. Quay's trading history.
Who are Atossa Genetics' active insiders?: Atossa Genetics' insider roster includes Steven Quay (Chairman of the Board and Chief Executive Officer), H. Lawrence Remmel (Director), and Gregory Weaver (Director). Learn More on Atossa Genetics' active insiders.

Steven C. Quay Insider Trading History at Atossa Genetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/21/2025	Buy	749	$13.20	$9,886.80	926
3/9/2016	Buy	1,000	$5.55	$5,550.00
1/19/2016	Buy	3,333	$3.00	$9,999.00
10/1/2013	Sell	484	$84.90	$41,091.60

Steven C. Quay Buying and Selling Activity at Atossa Genetics

Atossa Genetics Company Overview

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Today's Range

Now: $2.29

$1.96

$2.30

50 Day Range

MA: $2.39

$1.90

$2.79

2 Week Range

Now: $2.29

$1.70

$19.35

Volume

88,161 shs

Average Volume

117,033 shs

Market Capitalization

$22.80 million

P/E Ratio

N/A

Dividend Yield